Postpartum thyroiditis screening

Jump to navigation Jump to search

Postpartum thyroiditis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Postpartum Thyroiditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Postpartum thyroiditis screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Postpartum thyroiditis screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Postpartum thyroiditis screening

CDC on Postpartum thyroiditis screening

Postpartum thyroiditis screening in the news

Blogs on Postpartum thyroiditis screening

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Postpartum thyroiditis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is insufficient evidence to recommend routine screening for PPT. According to the American Journal of Obstetrics and Gynecology screening for postpartum thyroiditis by measuring anti-TPO antibodies is recommended every pregnant women. According to the Endocrinology and Metabolism Clinics of North America screening for postpartum thyroiditis in first trimester by measuring anti-TPO antibodies should be limited to every high-risk pregnant women with type 1 DM, history of postpartum thyroiditis and any patient with high risk should be followed with TSH levels every 6th and 9th postpartum period.

Screening

  • There is insufficient evidence to recommend routine screening for PPT.
  • According to the  American Journal of Obstetrics and Gynecology screening for postpartum thyroiditis by measuring anti-TPO antibodies is recommended every pregnant women.[1]
  • According to the Endocrinology and Metabolism Clinics of North America screening for postpartum thyroiditis in first trimester by measuring anti-TPO antibodies should be limited to every high risk pregnant women with: [2]

References

  1. Hayslip CC, Fein HG, O'Donnell VM, Friedman DS, Klein TA, Smallridge RC (1988). "The value of serum antimicrosomal antibody testing in screening for symptomatic postpartum thyroid dysfunction". Am J Obstet Gynecol. 159 (1): 203–9. PMID 3394739.
  2. Stagnaro-Green A (2000). "Recognizing, understanding, and treating postpartum thyroiditis". Endocrinol Metab Clin North Am. 29 (2): 417–30, ix. PMID 10874538.
  3. Keely EJ (2011). "Postpartum thyroiditis: an autoimmune thyroid disorder which predicts future thyroid health". Obstet Med. 4 (1): 7–11. doi:10.1258/om.2010.100041. PMC 4989649. PMID 27579088.

Template:WH Template:WS